Aptorum Group raises $2 million in registered direct offering

NEW YORK - Aptorum Group Limited (NASDAQ:APM), a clinical stage biopharmaceutical company with a current market capitalization of $12.7 million, announced Friday it has secured $2 million through a registered direct offering of 1 million Class A ordinary shares priced at $2.00 per share. According to InvestingPro analysis, the company appears undervalued based on its Fair Value assessment, with strong financial health indicators including a healthy current ratio of 2.98.

In a concurrent private placement, the company will issue unregistered warrants to purchase up to 2 million additional Class A ordinary shares at an exercise price of $2.00 per share. If fully exercised, these warrants could generate up to $4 million in additional gross proceeds. The company maintains a moderate debt level with a debt-to-equity ratio of 0.15, as reported by InvestingPro, which offers comprehensive financial analysis through its Pro Research Reports covering 1,400+ US equities.

H.C. Wainwright & Co. is serving as the exclusive placement agent for the transaction, which is expected to close around October 14, 2025, subject to customary closing conditions.

According to the press release, Aptorum plans to use the proceeds to fund expenses related to its previously announced merger agreement with DiamiR Biosciences Corp. and for general working capital of both companies pending the anticipated merger closing. The merger remains contingent on approval by Aptorum’s shareholders.

The ordinary shares are being offered through a shelf registration statement on Form F-3 that was declared effective by the SEC on January 19, 2023. The unregistered warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933.

The warrants will be exercisable upon issuance and will expire 24 months from the effective date of a registration statement registering the underlying shares for resale.

Aptorum Group focuses on developing therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases. The company has demonstrated strong momentum with a 225% price return over the past six months, though it remains unprofitable over the last twelve months. InvestingPro analysis reveals 8 additional key insights about the company’s financial health and market position.

In other recent news, Aptorum Group Limited has announced the appointment of Dr. Laura A. Philips to its board of directors. This appointment is set to become effective following the completion of Aptorum Group’s planned merger with DiamiR Biosciences Corp. Dr. Philips is the co-founder, President, and CEO of Spheryx, Inc., and brings a wealth of experience from her previous roles in various life sciences companies. Her past board memberships include WellGen, Delcath Systems, and China Yongxin Pharmaceuticals. Additionally, Dr. Philips has held executive positions at NexGenix Pharmaceuticals and Corning Incorporated, and she has experience from her service in the Clinton Administration. The merger and board appointment represent significant developments for Aptorum Group as it continues to expand its leadership team. These recent developments are part of Aptorum Group’s ongoing efforts to strengthen its strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.